0       0

Timely Topics in Transplantation Webcast Series


WEB150317 - Hepatitis C Treatment in Non-liver Solid Organ Transplant Recipients


Mar 17, 2015 2:00pm ‐ Mar 17, 2015 3:00pm


Credits: None available.

Standard: $25.00

Description

The diagnosis of chronic hepatitis C has been considered a relative or absolute contraindication for non-liver transplantation in the past, due to concerns of liver disease progression post-transplantation and a lack of safe and effective therapies. The recent availability of interferon-free, all-oral, antiviral drug combinations to treat of chronic hepatitis C provides an opportunity to revise management algorithms to optimize the care of non-liver transplant candidates and recipients.

Objectives:

  • Describe the components of the new HCV all-oral combinations, the role of ribavirin, and anticipated rates of HCV eradication with treatment
  • Summarize the safety data of new HCV therapies as it pertains to non-liver transplant candidates and recipients, including key drug-drug interactions (HCV antivirals and immunosuppressive drugs)
  • Evaluate the pros and cons of HCV treatment pre versus post-transplantation, including considerations related to use of anti-HCV positive donors

Speaker(s):

Credits

  • 0.00 - CE

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content
token-speaker-name image
token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content